(Total Views: 427)
Posted On: 05/11/2019 5:05:18 AM
Post# of 154804
Regarding NASH, yes, it is good that they will also move into this direction, since it is a potential market on which a lot of hype and "fantasy" is currently projected.
Also, let's not forget that Gilead's selonsertib just flunked two studies in NASH.
IMO Gilead would be the most natural fit for CYDY, given their strong cash position and the future areas PRO-140 will move into.
However, I think Nader's statement that those pre-clinical NASH companies have 1B market cap is way off. The most promising company (besides Genfit), GALT, which is about to initiate a Phase 3 study, currently has a market cap of about $300m, while their product has also shown extremely encouraging results in combination with Keytruda, and galectin-3 may serve as a biomarker that can predict success of Keytruda, which makes it extremely interesting for Merck (and their main competitor, Bristol-Myers). I think that their market cap also shows that the market does not really believe, after recent failures, that a "monotherapy" in NASH will succeed, but that combo is the way to go.
@sjacobs: Seems like you have researched GALT. Do you also have a position in GALT?
Also, let's not forget that Gilead's selonsertib just flunked two studies in NASH.
IMO Gilead would be the most natural fit for CYDY, given their strong cash position and the future areas PRO-140 will move into.
However, I think Nader's statement that those pre-clinical NASH companies have 1B market cap is way off. The most promising company (besides Genfit), GALT, which is about to initiate a Phase 3 study, currently has a market cap of about $300m, while their product has also shown extremely encouraging results in combination with Keytruda, and galectin-3 may serve as a biomarker that can predict success of Keytruda, which makes it extremely interesting for Merck (and their main competitor, Bristol-Myers). I think that their market cap also shows that the market does not really believe, after recent failures, that a "monotherapy" in NASH will succeed, but that combo is the way to go.
@sjacobs: Seems like you have researched GALT. Do you also have a position in GALT?
(0)
(0)
